Tonix signs sponsored research agreement for TNX-1500 to prevent GVHD following HSCT in animals
Dec. 7, 2022
Tonix Pharmaceuticals Holding Corp. has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for the prevention of graft-vs.-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) in animals.